Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
StockNews.AI · 2 hours
AI Summary
Sonoma reported fiscal 2026 revenue of $19.5 million, up 37% year over year, with Q4 revenue of $5.6 million, up 48%. US revenue for Q4 rose to $2.0 million, up 194% YoY. Net loss and EBITDA loss improved, cash on hand fell to $2.4 million; MoCRA registrations and a Medline wound-cleanser launch could catalyze longer-term growth.
Sentiment Rationale
Strong top-line growth, improved losses, and potential channel expansion via MoCRA approvals and Medline partnership could elicit a positive near-term price reaction, though liquidity constraints temper upside.
Trading Thesis
Bullish over the next 3–9 months on revenue momentum and improving EBITDA, despite liquidity risk.
Market-Moving
- US revenue momentum accelerates with new distributors.
- MoCRA registration and Medline wound-cleanser launch may expand channels.
- Cash balance declined to $2.4M, signaling liquidity risk.
- Gross margin remains around 38–39%, with potential upside from scale.
Key Facts
- Q4 2026 revenue $5.6M, up 48% YoY.
- FY2026 revenue $19.5M, up 37% YoY.
- US Q4 revenue $2.0M, up 194% YoY; FY US +117%.
- Net loss Q4 2026 $0.6M; EBITDA loss $0.2M, improvements.
- Cash and cash equivalents $2.4M as of 3/31/2026; liquidity risk remains.
Companies Mentioned
- Sonoma Pharmaceuticals, Inc. (SNOA): Primary subject; recent results show revenue growth and margin stability but liquidity risk.
- Medline Industries, LP (N/A): Private partner; wound-cleanser and broader distribution could boost near-term orders.
Earnings
Earnings; reflects revenue growth, narrowed losses, and strategic partnerships; catalysts include MoCRA milestones and Medline deal, with liquidity risk a key overhang.